Article Sidebar

PDF
Date Published: 25/03/2025
Online Published: 25/03/2025
Abstract Views: 365
Views PDF: 137
DOI: https://doi.org/10.58490/ctump.2025i85.3532
Issue
No. 85 (2025)
Section
Article
How to Cite
Doan, T. P. N., & Hoang, Q. B. (2025). EVALUATION OF THE OUTCOMES OF PHACOEMULSIFICATION WITH IMPLANTATION OF A NON-DIFFRACTIVE EDOF IOL FOR CATARACT TREATMENT AT CAN THO EYE, DENTAL AND MAXILLOFACIAL HOSPITAL IN 2023-2024. Cantho Journal of Medicine and Pharmacy, 85, 15-21. https://doi.org/10.58490/ctump.2025i85.3532

EVALUATION OF THE OUTCOMES OF PHACOEMULSIFICATION WITH IMPLANTATION OF A NON-DIFFRACTIVE EDOF IOL FOR CATARACT TREATMENT AT CAN THO EYE, DENTAL AND MAXILLOFACIAL HOSPITAL IN 2023-2024

Thi Phuong Nhi Doan1,, Quang Binh Hoang2
1 Can Tho University of Medicine and Pharmacy
2 Can Tho Eye, Dental and Maxillofacial Hospital

Main Article Content

Abstract

Background: Non-diffractive EDOF intraocular lenses fulfill visual demands while minimizing postoperative visual disturbances. Objectives: To evaluate the outcomes of phacoemulsification with AcrySof IQ Vivity IOL for cataract treatment at Can Tho Eye, Dental and


Maxillofacial Hospital from May 2023 to December 2024. Materials and methods: A clinical intervention study without a control group conducted on 43 eyes of 41 patients who underwent phacoemulsification with implantation of the AcrySof IQ Vivity IOL at Can Tho Eye, Dental and Maxillofacial Hospital. Results: The mean age of patients was 48.51 ± 10.1 years. UDVA at 1 week,


1 month, and 3 months postoperatively was 0.12 ± 0.15 logMAR, 0.10 ± 0.14 logMAR, and 0.10 ± 0.13 logMAR, respectively. UIVA at 1 week, 1 month, and 3 months was 0.15 ± 0.12 logMAR, 0.12 ± 0.13 logMAR, and 0.11 ± 0.13 logMAR, respectively. UNVA at 1 week, 1 month, and 3 months was 0.22 ± 0.15 logMAR, 0.22 ± 0.14 logMAR, and 0.22 ± 0.14 logMAR, respectively. CDVA, UIVA and CIVA showed significant improvement at 3 months compared to 1 week postoperatively (p < 0.05), whereas UDVA, UNVA and CNVA remained stable from the first postoperative week. The most common visual disturbances were halos, glare, and starbursts, which gradually diminished and resolved after 3 months. A high percentage of patients reported being very satisfied with the non-diffractive EDOF AcrySof IQ Vivity IOL. Conclusions: Phacoemulsification with nondiffractive EDOF IOL implantation provides excellent distance and intermediate vision while maintaining functional near vision. This approach preserves contrast sensitivity and minimizes postoperative visual disturbances, leading to high patient satisfaction.  

Article Details

Keywords

Phacoemulsification, visual acuity, Vivity IOL, EDOF

References

1. Flaxman SR, Bourne RR, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and metaanalysis. Lancet Glob Health. 2017. 5, e1221–e34.
2. Limburg H. Result of National Survey on Avoidable Blindness in Vietnam using RAAB methodology. Medical Service Administration of Vietnam Ministry of Health and Vietnam National Institute of Ophthalmology. 2015.10.
3. Hashemi H, Hatef E, Fotouhi A, Feizzadeh A, Mohammad K. The prevalence of lens opacities in Tehran: the Tehran Eye Study. Ophthalmic Epidemiol. 2009. 16, 187–92.
4. Kohnen T. Nondiffractive wavefront-shaping extended range-of-vision intraocular lens. J Cataract Refract Surg. 2020. 46(9):1312–3, doi:10.1097/j.jcrs.0000000000000247.
5. Kanclerz P, Toto F, Grzybowski A, Alio JL. Extended depth-of-field intraocular lenses: an update. Asia-Pac J Ophthalmol. 2020. 9(3), 194–202, doi:10.1097/APO.0000000000000296.
6. van Amelsfort T, Webers VS, Bauer NJ, Clement LH, van den Biggelaar FJ, Nuijts RM. Visual outcomes of a new nondiffractive extended depth-of-focus intraocular lens targeted for mini monovision: 3-month results of a prospective cohort study. J Cataract Refract Surg. 2022. 48(2),151–6, doi:10.1097/j.jcrs.0000000000000825.
7. Shafer BM, McCabe C, Reiser H, Newsom TH, Berdahl J. The REVIVE Study: Long Term Outcomes of a Novel Non-Diffractive Extended Vision IOL versus Monofocal Control IOL. Clin Ophthalmol. 2022. 16,3945-3950, https://doi.org/10.2147/OPTH.S390380.
8. Cummings AB, Savini G, Carones F, Kermani O, Ruiz-Mesa R. The Vivity IOL: The European experience. Curr Ophthalmol Rep. 2022. 10(1), 11–8, DOI:10.1007/s40135-022-00283-7.
9. Poyales M, Mearza A, Varma D, Balachandran C, Lemp-Hull J. Multi-Country Clinical Outcomes of a New Non-Diffractive Extended-Vision Intraocular Lens at Six Months Postoperatively. Presented at the 37th Congress of the European Society of Cataract & Refractive Surgeons (ESCRS). 2019.
10. Bhasin P, Sarkar D, Bhasin P, Dhanapal PP, Ubhal GN, Bhargava M. Visual performance and patient satisfaction with AcrySof® IQ Vivity® IOL: Experience from a tertiary care center in central India. Indian J Ophthalmol. 2024. 72(4), 554–7, doi:10.4103/IJO.IJO_1018_23.
11. Giannuzzi F, Carlà MM, Margollicci F, et al. Functional outcomes and quality of life after AcrySof IQ Vivity intraocular lens implantation in a real-world study. Sci Rep. 2024. 14, 20620, doi:10.1038/s41598-024-69960-w.